Mitosis, the tightly regulated process of somatic cell division, ensures accurate DNA replication and chromosome segregation. Disruptions—via proteotoxic stress, inflammation, oxidative damage, or interference with DNA repair—can promote genomic instability, apoptosis, or pathological proliferation. Comprehensive peer-reviewed research collections compiled by Dr. Martin Wucher, MSC Dent Sc (eq DDS), Dr. Byram Bridle, PhD, Dr. Steven Hatfill, Erik Sass, et al., along with independent studies, highlight potential interactions between mRNA-encoded SARS-CoV-2 spike protein (produced via COVID-19 mRNA vaccines) and cellular processes. These include prolonged antigen expression, protein misfolding/frameshifting, endothelial dysfunction leading to clotting, and signals potentially encouraging oncogenic or inflammatory vectors.

mRNA Vaccines and Spike Protein Production

mRNA vaccines deliver synthetic, modified mRNA in lipid nanoparticles (LNPs) that instructs cytoplasmic ribosomes to produce a stabilized SARS-CoV-2 spike protein. This elicits an immune response, but compiled evidence indicates the spike protein itself exhibits independent pathogenicity (“spikeopathy”), unrelated to the full virus.

Studies document prolonged spike expression and persistence. Vaccine mRNA and spike protein have been detected in tissues and circulation far beyond initial expectations, sometimes for months or longer. Exosomes carrying spike post-vaccination enable systemic distribution and continued low-level production or transfer.

Impacts on Mitosis and Cellular Division

Direct studies on mitosis are limited, but multiple mechanisms suggest disruption:

• Proteotoxic and frameshift effects: Modified mRNA can induce ribosomal frameshifting, producing aberrant proteins that burden cellular quality control (proteasomes, chaperones). Long-lasting biochemically modified mRNA and frameshifted recombinant spike proteins have been reported in human tissues and circulation after vaccination.
• Nuclear and DNA repair interference: Spike protein (or fragments) links in various models to oxidative stress, mitochondrial dysfunction, and inflammation that could impair mitotic fidelity. Hypotheses invoke retrotransposon activity or stem cell effects contributing to long-term tissue damage.
• Cell-type specific stress: In cardiomyocytes, endothelial cells, macrophages, and other lines, spike induces apoptosis, ROS production, and inflammatory signaling (e.g., NLRP3 inflammasome), which can affect proliferating cells during mitosis. Nuclear envelope breakdown during mitosis might increase exposure of genomic material to cytoplasmic spike or stress factors.

Continued Prevalence of Spike Protein

The collections emphasize biodistribution and persistence studies showing mRNA and spike reaching distant organs (heart, brain, etc.). Circulating spike or exosomes post-vaccination, along with tissue detection, supports ongoing or recurrent exposure. This contrasts with early claims of transient, localized production and raises concerns for cumulative cellular burden.

Protein Misfolding, “Blood Plague” Clots, and Coagulopathy

Spike protein interacts with coagulation pathways, endothelial cells, and platelets:

• It promotes barrier dysfunction, vascular leak, platelet activation, and prothrombotic states via mechanisms including ACE2 signaling, integrin/TGF-β, and direct effects on fibrin or hemagglutination. Amyloid-like misfolding or aggregation potential has been noted, alongside increased blood viscosity and thrombogenic factors.
• Clinical pathology reports link spike to microvascular disease, thrombosis, and inflammatory clots—sometimes framed as severe coagulopathy signals (“blood plague”). These effects appear in both infection and vaccine-induced spike contexts, with biodistribution enabling systemic impact. LNPs themselves contribute inflammatory toxicity, potentially exacerbating endothelial issues.

Cancer Encouragement Vectors and Genomic Risks

The collections include studies on long-term damage, mitochondrial perturbations, fibrosis, and hypotheses involving retrotransposons/stem cells in persistent tissue effects. A large South Korean population-based cohort (n=8,407,849) reported increased risks at 1 year post-vaccination for thyroid (HR 1.351), gastric (HR 1.335), colorectal (HR 1.283), lung (HR 1.533), breast (HR 1.197), and prostate (HR 1.687) cancers, varying by vaccine type, sex, and age.

Potential vectors include:

• Chronic inflammation and oxidative stress.
• Interference with DNA repair or cell cycle checkpoints.
• Immune modulation (e.g., imprinting or evasion mechanisms).
• Frameshifted or misfolded proteins adding proteotoxic load.

While direct causation of cancer is not uniformly established, the volume of evidence on genomic instability signals, rapid-onset phenomena in case reports, and multi-organ tropism warrants scrutiny. Some papers discuss spike’s role in promoting pro-inflammatory profiles in immune cells that could indirectly influence tumor microenvironments.

Broader Context from the Research Collections

This article draws from the most recent versions (July 1, 2025) of the “COVID-19 mRNA ‘vaccine’ harms research collection” (Version 2; >700 total studies across sections) and the “COVID-19 spike protein pathogenicity research library” (Version 3; n=375 papers), plus dedicated sections on biodistribution (n=61), persistence (n=41), LNP toxicity (n=80), and immune imprinting (n=140). It underscores that spike—whether from virus or vaccine—drives pathology via inflammation (NLRP3, cytokines), oxidative stress, mitochondrial changes, endothelial damage, and more. Many effects were studied using recombinant spike or pseudovirus models mirroring vaccine-produced antigen.

Additional supporting sources address spike-induced mechanisms relevant to mitotic disruption, clotting, and oncogenesis.

mRNA technology enabled a rapid response to COVID-19 but, per these sources, introduced concerns around prolonged expression, off-target distribution, and spike’s intrinsic toxicity. Benefits in reducing severe infection must be weighed against rare but documented adverse signals in susceptible individuals.

Further independent research, improved vaccine designs (e.g., minimizing persistence/frameshifting), and personalized risk assessment remain critical as platforms expand. Consult healthcare professionals for individual concerns. Science requires open examination of all signals in this compiled literature.

References

1. Wucher MW, Bridle B, Hatfill S, Sass E, et al. COVID-19 mRNA “vaccine” harms research collection. Version 2. Zenodo; July 1, 2025. doi:10.5281/zenodo.15787612. Available at: https://sarstat.org/pdfs/6867f19cb80ea.pdf. Accessed May 7, 2026.

2. Parry PI, Lefringhausen A, Turni C, et al. ‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines. 2023;11(8):2287. doi:10.3390/biomedicines11082287.

3. Kim HJ, Kim MH, Choi MG, Chun EM. 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea. Biomark Res. 2025;13:114. doi:10.1186/s40364-025-00831-w. Available at: https://sarstat.org/pdfs/68dd4155dd6d0.pdf. Accessed May 7, 2026.

4. Wucher M, et al. COVID-19 spike protein pathogenicity research library. Version 3. Zenodo; July 1, 2025. doi:10.5281/zenodo.14559644. (Subsection of the main collection).

5. Kim HJ, et al. (Supplementary materials and additional analyses from the Korean cohort). Biomark Res. 2025;13:114.

6. Almehdi AM, et al. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection. 2021;49(5):855-876. doi:10.1007/s15010-021-01677-8.

7. Angeli F, et al. COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the ‘Spike effect’. Eur J Intern Med. 2022;103:23-28. doi:10.1016/j.ejim.2022.06.015.

8. Bansal S, et al. Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines. J Immunol. 2021;207(10):2405-2410. doi:10.4049/jimmunol.2100637.

9. Baumeier C, et al. Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series. Int J Mol Sci. 2022;23(13):6940. doi:10.3390/ijms23136940.

10. Bellavite P, et al. Immune response and molecular mechanisms of cardiovascular adverse effects of spike proteins from SARS-CoV-2 and mRNA vaccines. Biomedicines. 2023;11(2):451. doi:10.3390/biomedicines11020451.

11. Balzanelli MG, et al. The Role of SARS-CoV-2 Spike Protein in Long-term Damage of Tissues and Organs, the Underestimated Role of Retrotransposons and Stem Cells, a Working Hypothesis. Endocr Metab Immune Disord Drug Targets. 2025;25(2):85-98. doi:10.2174/0118715303283480240227113401.